Ligand validation:7C52

PGV: (1R)-2-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-1-[(PALMITOYLOXY)METHYL]ETHYL (11E)-OCTADEC-11-ENOATE

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
7C52_PGV_H_303	17%	42%	0.275	0.908	1.1	1.19	2	4	2	0	71%	0.7059
7C52_PGV_D_106	17%	45%	0.272	0.904	1.12	1.05	2	3	2	0	69%	0.6863
7C52_PGV_C_508	12%	28%	0.267	0.899	1.45	1.56	3	3	0	0	41%	0.4118
7C52_PGV_L_307	8%	44%	0.338	0.841	0.99	1.22	2	4	4	0	84%	0.8431
7C52_PGV_9_104	7%	39%	0.305	0.824	1.16	1.31	2	6	4	0	65%	0.6471
7C52_PGV_M_411	4%	42%	0.44	0.854	1.06	1.24	2	4	3	0	73%	0.7255
7C52_PGV_3_105	4%	51%	0.409	0.771	0.94	0.97	2	2	5	0	100%	1
7C52_PGV_L_308	3%	46%	0.413	0.779	0.98	1.13	2	3	4	0	86%	0.8627
7C52_PGV_1_105	3%	40%	0.384	0.779	1.22	1.17	2	2	1	0	61%	0.6078
7C52_PGV_M_410	2%	49%	0.489	0.749	1.05	0.95	2	3	3	0	90%	0.902
5Y5S_PGV_M_413	40%	48%	0.162	0.891	1.06	0.97	2	4	3	0	90%	0.902
5B1A_PGV_P_303	98%	36%	0.064	0.985	1.06	1.51	3	13	4	0	100%	1
5X1B_PGV_C_302	95%	52%	0.078	0.981	0.92	0.93	2	4	0	0	100%	1
5B1B_PGV_C_302	94%	56%	0.078	0.979	0.81	0.87	1	1	3	0	100%	1
7YPY_PGV_P_302	94%	54%	0.079	0.978	0.79	0.99	2	2	1	0	100%	1
7COH_PGV_C_267	93%	49%	0.087	0.983	0.87	1.09	3	3	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.